Literature DB >> 20472556

Reduction of brain beta-amyloid (Abeta) by fluvastatin, a hydroxymethylglutaryl-CoA reductase inhibitor, through increase in degradation of amyloid precursor protein C-terminal fragments (APP-CTFs) and Abeta clearance.

Mitsuru Shinohara1, Naoyuki Sato, Hitomi Kurinami, Daisuke Takeuchi, Shuko Takeda, Munehisa Shimamura, Toshihide Yamashita, Yasuo Uchiyama, Hiromi Rakugi, Ryuichi Morishita.   

Abstract

Epidemiological studies suggest that statins (hydroxymethylglutaryl-CoA reductase inhibitors) could reduce the risk of Alzheimer disease. Although one possible explanation is through an effect on beta-amyloid (Abeta) metabolism, its effect remains to be elucidated. Here, we explored the molecular mechanisms of how statins influence Abeta metabolism. Fluvastatin at clinical doses significantly reduced Abeta and amyloid precursor protein C-terminal fragment (APP-CTF) levels among APP metabolites in the brain of C57BL/6 mice. Chronic intracerebroventricular infusion of lysosomal inhibitors blocked these effects, indicating that up-regulation of the lysosomal degradation of endogenous APP-CTFs is involved in reduced Abeta production. Biochemical analysis suggested that this was mediated by enhanced trafficking of APP-CTFs from endosomes to lysosomes, associated with marked changes of Rab proteins, which regulate endosomal function. In primary neurons, fluvastatin enhanced the degradation of APP-CTFs through an isoprenoid-dependent mechanism. Because our previous study suggests additive effects of fluvastatin on Abeta metabolism, we examined Abeta clearance rates by using the brain efflux index method and found its increased rates at high Abeta levels from brain. As LRP1 in brain microvessels was increased, up-regulation of LRP1-mediated Abeta clearance at the blood-brain barrier might be involved. In cultured brain microvessel endothelial cells, fluvastatin increased LRP1 and the uptake of Abeta, which was blocked by LRP1 antagonists, through an isoprenoid-dependent mechanism. Overall, the present study demonstrated that fluvastatin reduced Abeta level by an isoprenoid-dependent mechanism. These results have important implications for the development of disease-modifying therapy for Alzheimer disease as well as understanding of Abeta metabolism.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20472556      PMCID: PMC2903370          DOI: 10.1074/jbc.M110.102277

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  62 in total

1.  Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease.

Authors:  C A McLean; R A Cherny; F W Fraser; S J Fuller; M J Smith; K Beyreuther; A I Bush; C L Masters
Journal:  Ann Neurol       Date:  1999-12       Impact factor: 10.422

Review 2.  Small GTP-binding proteins.

Authors:  Y Takai; T Sasaki; T Matozaki
Journal:  Physiol Rev       Date:  2001-01       Impact factor: 37.312

3.  Simvastatin strongly reduces levels of Alzheimer's disease beta -amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo.

Authors:  K Fassbender; M Simons; C Bergmann; M Stroick; D Lutjohann; P Keller; H Runz; S Kuhl; T Bertsch; K von Bergmann; M Hennerici; K Beyreuther; T Hartmann
Journal:  Proc Natl Acad Sci U S A       Date:  2001-04-10       Impact factor: 11.205

4.  Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the alpha -secretase ADAM 10.

Authors:  E Kojro; G Gimpl; S Lammich; W Marz; F Fahrenholz
Journal:  Proc Natl Acad Sci U S A       Date:  2001-04-17       Impact factor: 11.205

Review 5.  Isoprenoids as mediators of the biological effects of statins.

Authors:  James K Liao
Journal:  J Clin Invest       Date:  2002-08       Impact factor: 14.808

6.  Statins and the risk of dementia.

Authors:  H Jick; G L Zornberg; S S Jick; S Seshadri; D A Drachman
Journal:  Lancet       Date:  2000-11-11       Impact factor: 79.321

7.  Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier.

Authors:  M Shibata; S Yamada; S R Kumar; M Calero; J Bading; B Frangione; D M Holtzman; C A Miller; D K Strickland; J Ghiso; B V Zlokovic
Journal:  J Clin Invest       Date:  2000-12       Impact factor: 14.808

8.  Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors.

Authors:  B Wolozin; W Kellman; P Ruosseau; G G Celesia; G Siegel
Journal:  Arch Neurol       Date:  2000-10

Review 9.  HMG-Co A reductase inhibitors in the treatment of cardiovascular diseases: stabilization of coronary artery plaque.

Authors:  Ryuichi Morishita; Naruya Tomita; Toshio Ogihara
Journal:  Curr Drug Targets       Date:  2002-10       Impact factor: 3.465

10.  Regulation of the brain isoprenoids farnesyl- and geranylgeranylpyrophosphate is altered in male Alzheimer patients.

Authors:  Gunter P Eckert; Gero P Hooff; Dana M Strandjord; Urule Igbavboa; Dietrich A Volmer; Walter E Müller; W Gibson Wood
Journal:  Neurobiol Dis       Date:  2009-05-21       Impact factor: 5.996

View more
  50 in total

Review 1.  Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders.

Authors:  Berislav V Zlokovic
Journal:  Nat Rev Neurosci       Date:  2011-11-03       Impact factor: 34.870

2.  Enhanced brain amyloid-β clearance by rifampicin and caffeine as a possible protective mechanism against Alzheimer's disease.

Authors:  Hisham Qosa; Alaa H Abuznait; Ronald A Hill; Amal Kaddoumi
Journal:  J Alzheimers Dis       Date:  2012       Impact factor: 4.472

Review 3.  Dissecting Complex and Multifactorial Nature of Alzheimer's Disease Pathogenesis: a Clinical, Genomic, and Systems Biology Perspective.

Authors:  Puneet Talwar; Juhi Sinha; Sandeep Grover; Chitra Rawat; Suman Kushwaha; Rachna Agarwal; Vibha Taneja; Ritushree Kukreti
Journal:  Mol Neurobiol       Date:  2015-09-09       Impact factor: 5.590

4.  Modulation of amyloid precursor protein expression reduces β-amyloid deposition in a mouse model.

Authors:  Ayodeji A Asuni; Maitea Guridi; Joanna E Pankiewicz; Sandrine Sanchez; Martin J Sadowski
Journal:  Ann Neurol       Date:  2014-04-28       Impact factor: 10.422

Review 5.  MicroRNA: a connecting road between apoptosis and cholesterol metabolism.

Authors:  Yogita K Adlakha; Neeru Saini
Journal:  Tumour Biol       Date:  2016-04-22

Review 6.  Promoting the clearance of neurotoxic proteins in neurodegenerative disorders of ageing.

Authors:  Barry Boland; Wai Haung Yu; Olga Corti; Bertrand Mollereau; Alexandre Henriques; Erwan Bezard; Greg M Pastores; David C Rubinsztein; Ralph A Nixon; Michael R Duchen; Giovanna R Mallucci; Guido Kroemer; Beth Levine; Eeva-Liisa Eskelinen; Fanny Mochel; Michael Spedding; Caroline Louis; Olivier R Martin; Mark J Millan
Journal:  Nat Rev Drug Discov       Date:  2018-08-17       Impact factor: 84.694

Review 7.  Low-density lipoprotein receptor-related protein 1: a physiological Aβ homeostatic mechanism with multiple therapeutic opportunities.

Authors:  Abhay P Sagare; Rashid Deane; Berislav V Zlokovic
Journal:  Pharmacol Ther       Date:  2012-07-20       Impact factor: 12.310

8.  Olive-oil-derived oleocanthal enhances β-amyloid clearance as a potential neuroprotective mechanism against Alzheimer's disease: in vitro and in vivo studies.

Authors:  Alaa H Abuznait; Hisham Qosa; Belnaser A Busnena; Khalid A El Sayed; Amal Kaddoumi
Journal:  ACS Chem Neurosci       Date:  2013-02-25       Impact factor: 4.418

Review 9.  ApoE and Aβ in Alzheimer's disease: accidental encounters or partners?

Authors:  Takahisa Kanekiyo; Huaxi Xu; Guojun Bu
Journal:  Neuron       Date:  2014-02-19       Impact factor: 17.173

10.  LRP1 in brain vascular smooth muscle cells mediates local clearance of Alzheimer's amyloid-β.

Authors:  Takahisa Kanekiyo; Chia-Chen Liu; Mitsuru Shinohara; Jie Li; Guojun Bu
Journal:  J Neurosci       Date:  2012-11-14       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.